Robert Boorstein, MD, PhD
Associate Professor, Pathology, NEW YORK UNIVERSITY (INC)
Member of the Healthcare Council
Council Member Biography
Robert Boorstein, MD, PhD, is an Associate Professor in the Department of Pathology at New York University School of Medicine, where he directs clinical pathology training. Previously, Dr. Boorstein was the Director of Pathology at Bellevue Hospital and the Medical Director for Pathology and Laboratory Medicine of the South Manhattan Healthcare Network and Northern Manhattan and Generations Plus Health Network of the New York Center Health and Hospitals for over 13 years. He has experience in providing high volume laboratory services, with extensive expertise in automation, laboratory design, molecular diagnostics and other emerging technologies. Dr. Boorstein's basic science interests have focused on mechanisms of DNA damage and repair, and targets of anti-neoplastic therapy. He is an expert in the linkage between diagnostics and therapeutics. (This is me - Update Profile)
Employment History
- 1996 - 2008
- Director, Pathology, Bellevue Hospital Center
- 1983 - present
- Associate Professor, Pathology, NEW YORK UNIVERSITY (INC)
GLG NewsSM Analyses by Robert Boorstein, MD, PhD(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
What is potential future for Sequenom in prenatal testing.
November 9, 2009
Robert Boorstein, MD, PhD, Associate Professor, Pathology, NEW YORK UNIVERSITY (INC)
So Where Does Sequenom’s Prenatal Play Currently Stand? | www.genomeweb.com
The historic but minimally supported enthusiasm for the Sequenom prenatal test has previously been reported in this space previously. Even in the absence of data retractions, leading to termination of much of senior management, problems in the rollout of the product should have been anticipated.Remarkably,...
-
Potential impact of large clinical trial on Liquid based cytology market
November 5, 2009
Robert Boorstein, MD, PhD, Associate Professor, Pathology, NEW YORK UNIVERSITY (INC)
Alternative to Pap Test Does Not Appear to Be Better for Detecting Cervical Cancer | www.medcompare.com
The data confirms what has long been known. There has never been definitive evidence for a benefit for Liquid based cytology screening compared with conventional screening, especially when sample collection is standardized and the laboratory meets reasonable standards.Objectively, liquid based cytology...
-
New entrant to DTC genetic testing market raises regulatory and financial questions
July 16, 2009
Robert Boorstein, MD, PhD, Associate Professor, Pathology, NEW YORK UNIVERSITY (INC)
New DTC Genetics Firm Pathway Genomics Launches | www.genomeweb.com
Pathway Genomics is the latest entrant into the DTC genetic testing market. They offer an extensive amount of genetic information (over 90 individual results) at a price point of $250. This undercuts both existing DTC providers, like 23andme, decode genetics, etc., but also appropriately...
-
Analyst upgrades of Genomic Health: Lagging or leading indicator
June 12, 2009
Robert Boorstein, MD, PhD, Associate Professor, Pathology, NEW YORK UNIVERSITY (INC)
Analyst Upgrades Genomic Health | www.genomeweb.com
Genomic Health is a molecular diagnostic company with one major product on the market and others potentially in the pipeline. Wall street has had only modest coverage of this company and generally assessments have been neutral. In assessing this company, it is important to recognize...
Leading institutions connect with Robert Boorstein, MD, PhD through GLG
GLG Study Groups with Robert Boorstein, MD, PhD(?)
| Study Group Name | No. Members |
|---|---|
| Multiple Myeloma Physicians | 211 |
| Luminex 100 System Users | 20 |
| Physicians who Treat Multiple Myeloma (US) | 183 |
| Pathologists (US) | 792 |
GLG Live Meetings with Robert Boorstein, MD, PhD(?)
Robert Boorstein, MD, PhD has not participated in any GLG Live Meetings.